(PRAX) Praxis Precision Medicines - Overview
Stock: Ulixacaltamide, Vormatrigine, Relutrigine, Elsunersen, PRAX-020
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 87.4% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.21 |
| Alpha | 251.84 |
| Character TTM | |
|---|---|
| Beta | 0.542 |
| Beta Downside | 1.604 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.59% |
| CAGR/Max DD | 0.96 |
Description: PRAX Praxis Precision Medicines January 21, 2026
Praxis Precision Medicines (NASDAQ:PRAX) is a Boston-based, clinical-stage biotech that targets central nervous system (CNS) disorders driven by neuronal excitation-inhibition imbalance, using two core platforms: “Cerebrum” for orally available small-molecule precision therapies and “Solidus” for antisense oligonucleotide (ASO) programs.
Its lead assets include Ulixacaltamide, a T-type calcium-channel blocker currently in Phase 3 for essential tremor, and Vormatrigine, a sodium-channel modulator in Phase 2/3 for focal-onset epilepsy. Additional candidates-Relutrigine (developmental and epileptic encephalopathies), PRAX-020 (KCNT1-related epilepsy), PRAX-050, and a suite of ASOs (Elsunersen, PRAX-080, PRAX-090, PRAX-100) targeting SCN2A, PCDH19, and SYNGAP1 mutations-are at various pre-clinical or early-clinical stages.
Key sector drivers that shape Praxis’s upside include the > $70 billion global market for CNS therapeutics and a growing payer willingness to reimburse precision-medicine approaches. As of the most recent 10-Q, the company reported a cash runway of roughly 12 months and a 2023 R&D spend of $85 million, underscoring the importance of the upcoming Phase 3 readout for Ulixacaltamide as a near-term catalyst. The firm’s strategic collaborations with Ionis Pharmaceuticals and a licensing deal with RogCon provide both technical expertise and potential milestone revenue streams.
For a deeper quantitative assessment, you may find ValueRay’s analyst dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -273.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.58 > 0.02 and ΔFCF/TA -33.82 > 1.0 |
| NWC/Revenue: 2961 % < 20% (prev 20.4k%; Δ -17.4k% < -1%) |
| CFO/TA -0.58 > 3% & CFO -228.2m > Net Income -273.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (22.0m) vs 12m ago 16.38% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.84% > 50% (prev 0.39%; Δ 1.45% > 0%) |
| Interest Coverage Ratio: -18.45 > 6 (EBITDA TTM -288.5m / Interest Expense TTM -15.6m) |
Altman Z'' -15.00
| A: 0.56 (Total Current Assets 273.8m - Total Current Liabilities 52.9m) / Total Assets 396.4m |
| B: -2.65 (Retained Earnings -1.05b / Total Assets 396.4m) |
| C: -0.71 (EBIT TTM -288.7m / Avg Total Assets 406.3m) |
| D: -19.87 (Book Value of Equity -1.05b / Total Liabilities 52.9m) |
| Altman-Z'' Score: -30.62 = D |
What is the price of PRAX shares?
Over the past week, the price has changed by +1.77%, over one month by +17.10%, over three months by +85.42% and over the past year by +265.60%.
Is PRAX a buy, sell or hold?
- StrongBuy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the PRAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 512.5 | 60.4% |
| Analysts Target Price | 512.5 | 60.4% |
| ValueRay Target Price | 322.4 | 0.9% |
PRAX Fundamental Data Overview January 31, 2026
P/B = 25.0664
Revenue TTM = 7.46m USD
EBIT TTM = -288.7m USD
EBITDA TTM = -288.5m USD
Long Term Debt = 436.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 436.0k USD (from shortTermDebt, last quarter)
Debt = 436.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -149.1m USD (from netDebt column, last quarter)
Enterprise Value = 8.45b USD (8.72b + Debt 436.0k - CCE 267.2m)
Interest Coverage Ratio = -18.45 (Ebit TTM -288.7m / Interest Expense TTM -15.6m)
EV/FCF = -37.01x (Enterprise Value 8.45b / FCF TTM -228.4m)
FCF Yield = -2.70% (FCF TTM -228.4m / Enterprise Value 8.45b)
FCF Margin = -3060 % (FCF TTM -228.4m / Revenue TTM 7.46m)
Net Margin = -3659 % (Net Income TTM -273.0m / Revenue TTM 7.46m)
Gross Margin = -3195 % ((Revenue TTM 7.46m - Cost of Revenue TTM 245.9m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 21.32 (Enterprise Value 8.45b / Total Assets 396.4m)
Interest Expense / Debt = 24.31% (Interest Expense 106.0k / Debt 436.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -228.1m (EBIT -288.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.18 (Total Current Assets 273.8m / Total Current Liabilities 52.9m)
Debt / Equity = 0.00 (Debt 436.0k / totalStockholderEquity, last quarter 343.5m)
Debt / EBITDA = 0.52 (negative EBITDA) (Net Debt -149.1m / EBITDA -288.5m)
Debt / FCF = 0.65 (negative FCF - burning cash) (Net Debt -149.1m / FCF TTM -228.4m)
Total Stockholder Equity = 408.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.20% (Net Income -273.0m / Total Assets 396.4m)
RoE = -66.90% (Net Income TTM -273.0m / Total Stockholder Equity 408.1m)
RoCE = -70.66% (EBIT -288.7m / Capital Employed (Equity 408.1m + L.T.Debt 436.0k))
RoIC = -55.88% (negative operating profit) (NOPAT -228.1m / Invested Capital 408.1m)
WACC = 7.91% (E(8.72b)/V(8.72b) * Re(7.91%) + D(436.0k)/V(8.72b) * Rd(24.31%) * (1-Tc(0.21)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 55.74%
Fair Price DCF = unknown (Cash Flow -228.4m)
EPS Correlation: -34.35 | EPS CAGR: 16.10% | SUE: 4.0 | # QB: 1
Revenue Correlation: 25.15 | Revenue CAGR: 0.0% | SUE: -0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-3.32 | Chg30d=+0.064 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-12.56 | Chg30d=+0.071 | Revisions Net=+0 | Growth EPS=+4.0% | Growth Revenue=+13067.6%